Literature DB >> 11493613

Expression of CD94 and NKG2 molecules on human CD4(+) T cells in response to CD3-mediated stimulation.

P Romero1, C Ortega, A Palma, I J Molina, J Peña, M Santamaría.   

Abstract

We investigated the ability of human peripheral CD4(+) cells to express CD94 and NKG2 molecules as a consequence of CD3-mediated activation. Using highly purified peripheral CD4(+) T cells, we found expression of both CD94 and NKG2A 15 days after CD3-mediated stimulation of cells. We also determined by reverse transcriptase-PCR that all gene members of NKG2 family-namely, NKG2A, -C, -D, and -E-are sequentially expressed on CD4(+) cells. We found that this expression is tightly regulated by cytokines, and we identified transforming growth factor-beta1 and interleukin-10 as the main factors that, on CD3-dependent stimulation, positively contribute to the expression of CD94 and NKG2A on CD4(+) cells. We also investigated the functional role of NKG2A and found that coligation of CD3 and NKG2A by specific monoclonal antibodies results in significant inhibition of interferon gamma and tumor necrosis factor alpha production by stimulated CD4(+) cells. The presence and function of these receptors on CD4(+) lymphocytes support a more general role for NKG2 molecules, whose functions were originally thought to be confined to cytotoxic cells, in the immune system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493613

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  9 in total

Review 1.  The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance.

Authors:  Francisco Borrego; Madhan Masilamani; Alina I Marusina; Xiaobin Tang; John E Coligan
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  NKG2A and CD56 are coexpressed on activated TH2 but not TH1 lymphocytes.

Authors:  Robert J Freishtat; Lindsay W Mitchell; Svetlana D Ghimbovschi; Samuel B Meyers; Eric P Hoffman
Journal:  Hum Immunol       Date:  2006-03-27       Impact factor: 2.850

3.  Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy.

Authors:  Jeffrey Mao-Hwa Liu; Ping Chen; Molly Javier Uyeda; Brandon Cieniewicz; Ece Canan Sayitoglu; Benjamin Craig Thomas; Yohei Sato; Rosa Bacchetta; Alma-Martina Cepika; Maria Grazia Roncarolo
Journal:  Cytotherapy       Date:  2021-08-15       Impact factor: 5.414

4.  Differential analysis of CD4+ Th memory clones with identical T-cell receptor (TCR)-alphabeta rearrangement (non-transgenic), but distinct lymphokine phenotype, reveals diverse and novel gene expression.

Authors:  Christine M Graham; D Brian Thomas
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

5.  Differential induction of CD94 and NKG2 in CD4 helper T cells. A consequence of influenza virus infection and interferon-gamma?

Authors:  Christine M Graham; Jillian R Christensen; D Brian Thomas
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

6.  Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT Cells.

Authors:  Ilona Hromadnikova; Shuang Li; Katerina Kotlabova; Anne M Dickinson
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

Review 7.  Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection.

Authors:  Angelique Hölzemer; Wilfredo F Garcia-Beltran; Marcus Altfeld
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

Review 8.  Towards Clinical Translation of CD8+ Regulatory T Cells Restricted by Non-Classical Major Histocompatibility Complex Ib Molecules.

Authors:  Samiksha Wasnik; David J Baylink; Jianmei Leavenworth; Chenfan Liu; Hongzheng Bi; Xiaolei Tang
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

Review 9.  Implications of NKG2A in immunity and immune-mediated diseases.

Authors:  Xiaotong Wang; Huabao Xiong; Zhaochen Ning
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.